Comparative Effect of Cylindrical Lenses Verses Spherical Equilient on Contrast Sensitivity

May 6, 2024 updated by: Muhammad Naveed Babur, Superior University
the concept of spherical equivalent plays a pivotal role in simplifying the prescription and enhancing communication between eye care professionals and patients. The spherical equivalent is a calculated value that condenses the spherical and cylindrical components into a single power.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Detailed Description

Mathematically, it is determined by adding half of the cylindrical power to the spherical power (SE = Sphere + (Cylinder/2)). This calculated value serves as a convenient representation of the overall refractive error, aiding in a more straightforward understanding of the prescription. Understanding their individual and collective impact on contrast sensitivity opens up new avenues for refining corrective interventions and enhancing the overall quality of vision. This article aims to demystify the intricate relationship between spherical equivalent and cylindrical correction, and their collective impact on contrast sensitivity.

Study Type

Interventional

Enrollment (Actual)

68

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Punjab
      • Lahore, Punjab, Pakistan
        • Sehat Medical Complex Hanjarwal

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Patients within 18 to 35 years will be included.
  • Both genders will be included.
  • Patients having astigmatism will be included.
  • Patients having 6/6 corrected vision will be included.
  • Eyes having no other ocular pathology will be included.
  • Patients having no history of ocular surgery or corneal scar will be included.

Exclusion Criteria:

  • i. Eyes having any ocular pathology will be excluded.
  • Patients with corneal suture will be excluded.
  • Those using contact lenses instead of spectacles for vision correction will be excluded.
  • Participants with a history of eye surgery within the past year will be excluded.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Contrast sensitivity
Diagnostic test: Contrast sensitivity
Contrast sensitivity will be assessed by using two different techniques of refraction on is Cylinderical lens and other is Spherical equivalent
Other: Refraction
Other: Refraction
Refraction will be performed and contrast sensitivity will be assessed to assess patient comfort level and compliance.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Contrast sensitivity
Time Frame: 12 Months
The ability to perceive sharp and clear outlines of very small objects. It is also defined as the ability to identify minute differences in the shadings and patterns. CS helps detect objects without a clear outline and distinguish them from their background contrast
12 Months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Superior University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 1, 2023

Primary Completion (Actual)

March 1, 2024

Study Completion (Estimated)

September 1, 2024

Study Registration Dates

First Submitted

May 2, 2024

First Submitted That Met QC Criteria

May 6, 2024

First Posted (Actual)

May 9, 2024

Study Record Updates

Last Update Posted (Actual)

May 9, 2024

Last Update Submitted That Met QC Criteria

May 6, 2024

Last Verified

May 1, 2024

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MSRSW/Batch-Fall22/702

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Low Vision Aids

Clinical Trials on Contrast sensitivity

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mozambique

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe